Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
Reexamination Certificate
2009-04-03
2010-10-05
Parsa, Jafar (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Four or more ring nitrogens in the bicyclo ring system
Reexamination Certificate
active
07807830
ABSTRACT:
The present invention provides an improved process of preparing hydralazine hydrochloride, which involves the preparation of 1-chlorophthalazine salt and further reacting with hydrazine followed by purification of hydralazine hydrochloride, which is free of phosphate, does not contain any individual impurities more than 0.05%, total impurities less than 0.5%, and a hydrazine content of not more than 0.001%, and preferably less than 0.0003%. One benefit of improved purity is enhanced storage stability.
REFERENCES:
patent: 2484029 (1949-10-01), Hartmann et al.
patent: 4868179 (1989-09-01), Cohn
patent: 6465463 (2002-10-01), Cohn et al.
patent: 6784177 (2004-08-01), Cohn et al.
patent: 2003/0212272 (2003-11-01), Barbeau
patent: 2005/0137198 (2005-06-01), Nelson et al.
patent: 2005/0137397 (2005-06-01), Nelson
patent: 629177 (1949-09-01), None
Oates; “Antihypertensive Agents and Drug Therapy of Hypertension”; Goodman & Gilman's The Pharmacological Basis of Therapeutics (9th ed.), pp. 780-808, H; (New York: McGraw/Hill); 1996.
McFadden, et al.; “Cor pulmonale”; Heart Diseases. A Textbook of Cardiovascular-Medicine; 4th ed.; Philadelphia: WB Saunders, 1992; pp. 1581-1601.
Isaac; “Hydralazine and Psoriasis” British Medical Journal; 285:744; Sep. 11, 1982; 2 pages (abstract only).
Franciosa et al; “Hydralazine in the long-term Treatment of Chronic Heart Failure: Lack of Difference from Placebo”; Am. Heart .1, vol. 104, pp. 587-594 (1982).
Lessen, et al.; “Interactions Between Drug Substances and Excipients. 1. Fluorescence and HPLC Studies of Triazolophthalazine Derivatives from Hydralazine Hydrochloride and Starch”; J. Pharmaceutical Sci., 85(3): 326-329 (1996).
Chatterjee, et al.; “Oral Hydralazine in Chronic Heart Failure: Sustained Beneficial Hemodynamic Effects”; Annals of Internal Medicine; vol. 92; 1980; pp. 600-604.
Sinha and Motten; “Oxidative Metabolism of Hydralazine. Evidence for Nitrogen Centered Radicals Formation”; Biochemical and Biophysical Research Communications 105 (3); 1044-1051 (1982).
Gallagher, et al.; “Pharmacologic Approach to the Critically Ill Obstetric Patient,” p. 847-862; The Pharmacologic Approach to the Critically Ill Patient; 3rd ed., Chernow, B (ed.) (Oates, IA: Williams & Wilkins, 1995).
Artman, et al.; “Short-term hemodynamic effects of hydralazine in infants with complete arterioventricular canal defects”; Circulation, 69; pp. 949-954 (1984).
Binkley, et al.; “Usefulness of hydralazine to withdraw from dobutamine in severe congestive heart failure”; Am. Cardia, 68:1103-1106 (1991).
Jobdevairakkam Christopher N.
Kannappan Jayaraman
Rangisetty Jagadeesh B.
Navinta LLC
Parsa Jafar
St. Onge Steward Johnston & Reens LLC
LandOfFree
Manufacture of pure hydralazine salts does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Manufacture of pure hydralazine salts, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Manufacture of pure hydralazine salts will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4171913